Boehringer Ingelheim ( Boehringer-Ingelheim )


Boehringer Ingelheim's picture

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes.

Boehringer-Ingelheim press release, blog etc

01/03/2018 - 04:01 Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M
12/19/2017 - 02:55 Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
12/18/2017 - 04:34 Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
12/15/2017 - 04:26 Change in the Board of Managing Directors at Boehringer Ingelheim
12/11/2017 - 08:48 Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
11/20/2017 - 04:59 Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via to unlock their full potential
11/08/2017 - 03:12 Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
11/02/2017 - 06:45 Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
10/30/2017 - 04:00 Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
09/29/2017 - 10:46 Boehringer Ingelheim and FEI partner to promote equine health and education
09/28/2017 - 08:07 Boehringer Ingelheim joins forces with partners around the world towards the elimination of rabies
09/07/2017 - 10:28 Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments
09/07/2017 - 07:47 Boehringer Ingelheim is initiating Phase IIa study for the development of a new treatment for diabetic retinopathy a leading cause of vision-loss
08/24/2017 - 05:27 Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
08/03/2017 - 05:07 Next generation of veterinary scientists gathers at National Institutes of Health for National Veterinary Scholars Symposium
08/02/2017 - 02:12 Boehringer Ingelheim achieves good growth in the first half of 2017
07/23/2017 - 22:35 People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey